Oleksandr Nevzghoda

Oleksandr Nevzghoda

Auto-generated profile, based on publicly available information

Oleksandr Nevzghoda

Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 July 2025 in Tuberculosis, Lung Diseases, HIV Infection
Verified
Journal Article
Open access
PDF file
ONO.A. Nevzghoda
O.A. Nevzghoda
VSV.V. Shapovalov
V.V. Shapovalov
VSViktoriia Shapovalova
Viktoriia Shapovalova
АОАліна Осинцева
Аліна Осинцева
RPR.H. Protsiuk
R.H. Protsiuk
РПР.г. Процюк
Р.г. Процюк
Antibiotic therapy is one of the key methods of treating bacterial infections, including intracellular pathogens and tuberculosis. The choice of effective antibacterial drugs largely depends on their ability to penetrate cells and destroy pathogens that persist in macrophages and body tissues. Objective — to conduct ABC (Always Better Control) and VED (Vital, Essential, Desirable) analysis of antibiotics active against intracellular microorganisms and tuberculosis; to characterise the clinical and pharmacological groups of macrolides, fluoroquinolones and rifampicins, to determine their role in the pharmacotherapy of tuberculosis and other intracellular infections; to assess the feasibility of using these antibiotics, considering their effectiveness, safety, pharmacokinetic properties and compliance with modern clinical guidelines. Materials and methods. For the study, data on annual consumption and costs of antibiotics active against intracellular microorganisms and tuberculosis were collected in the period 2020—2024. The obtained data were systematised and entered into an MS spreadsheet. Statistical analysis was carried out using the built-in statistical functions of MS Excel. ABC analysis. Annual costs for individual drugs were arranged in descending order. The total cost of all drugs was calculated, as well as their percentage contribution to total costs. The resulting list was divided into three categories: category A — antibiotics which account for approximately 70 % of the total cost of consumption; category B — drugs accounting for about 20 % of costs; category C — antibiotics with the lowest level of costs (about 10 %). VED analysis. The assessment of the criticality of antibiotics was carried out by classifying drugs into three groups: vital (V), essential (E) and desirable (D). To determine the criticality of medicines, the following were conducted: a survey of doctors involved in pharmacotherapy of patients with intracellular infections and tuberculosis; a survey of pharmacists regarding the availability of medicines on the Ukrainian pharmaceutical; regulatory analysis. Group V includes medicines that are critically important for the survival of patients and must be available at any time. Group E includes medicines whose short-term absence will not lead to serious complications. Group D includes antibiotics with the least criticality, the absence of which will not have a significant impact on the treatment process. The final distribution of antibiotics by VED categories was discussed by an expert group consisting of physicians, surgeons, pulmonologists, phthisiologists and clinical pharmacists. Results and discussion. In the process of conducting ABC and VED analysis, a group of antibiotics active against intracellular microorganisms and tuberculosis was considered. This group includes drugs from different pharmacological classes, in particular: macrolides (erythromycin, spiramycin, clarithromycin); fluoroquinolones (levofloxacin, moxifloxacin); rifampicins (rifampicin combinations). The selection of medicines for the treatment of tuberculosis and intracellular infections was carried out by a multidisciplinary commission consisting of doctors and pharmacists. When selecting drugs, the commission considered the following key criteria: the presence of state registration in Ukraine; form of release; concentration of the active substance; pharmacological features. 42 antibiotics were selected. For each medicine, its trade name, dosage form, composition of the active substance, manufacturer and registration certificate in Ukraine are indicated. All drugs have valid licenses and registrations, which confirms their availability for medical use. Conclusions. Analysis of the distribution of antibiotics by categories A, B, C and VED allows us to assess the effectiveness of their use and the costs of pharmacotherapy in the treatment of intracellular infections and tuberculosis. The highest costs are for category A drugs, which confirms their importance in the treatment of these diseases. Category B drugs occupy the middle position in terms of costs, and category C account for the smallest share. The analysis also showed that most antibiotics are essential, which highlights their critical role in medical treatment. This allows for cost optimisation and improved pharmacotherapy in medical institutions.

20 June 2025 in Proceeding of the Shevchenko Scientific Society. Medical Sciences
Verified
Journal Article
Open access
PDF file
ONOleksandr Nevzghoda
Oleksandr Nevzghoda
АОАліна Осинцева
Аліна Осинцева
VSViktoriia Shapovalova
Viktoriia Shapovalova
ITIurii Titarenko
Iurii Titarenko
VSValentyn Shapovalov
Valentyn Shapovalov
VDViktoria Dovzhuk
Viktoria Dovzhuk
Background. Chronic pancreatitis (CP) is a progressive inflammatory disease that leads to irreversible damage to the pancreas, causing exocrine and endocrine insufficiency. The optimization of CP pharmacotherapy is a critical issue due to the increasing prevalence of the disease and the need for cost-effective and evidence-based treatment strategies. The use of ABC/VED analysis provides an opportunity to classify and prioritize medications based on their clinical significance and economic feasibility. Objective. The study aimed to optimize the pharmacotherapy of chronic pancreatitis by applying ABC/VED analysis in the context of marketing and pharmacoeconomic research. Methods. The research included a comprehensive review of regulatory documents, clinical guidelines, and pharmacoeconomic evaluations. A multidisciplinary expert survey was conducted involving 50 healthcare professionals, including gastroenterologists, surgeons, endocrinologists, general practitioners, and pharmacists. ABC analysis was applied to classify medications based on their cost contribution, while VED analysis categorized drugs into vital (V), essential (E), and desirable (D) groups. The study also assessed the regulatory framework for CP pharmacotherapy at national and international levels. Results. The study identified inconsistencies between national and international regulatory documents regarding CP pharmacotherapy. Among 30 analyzed medications, five drugs (Imipenem + Cilastatin, Meropenem, Metronidazole, Cefotaxime, Ciprofloxacin) were included in all four regulatory documents. ABC analysis showed that 82.21% of total expenditures were allocated to category A drugs, 15.54% to category B, and 2.25% to category C. VED analysis revealed that 43% of drugs were classified as vital, while 57% were essential, with no drugs considered non-essential. A combined ABC/VED matrix indicated that category A/V drugs had the highest expenditure share (41.54%), highlighting their priority in CP treatment. Conclusions. The application of ABC/VED analysis in CP pharmacotherapy enables a structured and economically justified approach to medication selection. The study revealed regulatory discrepancies that may impact drug accessibility and treatment effectiveness. The findings provide evidence-based recommendations for optimizing CP pharmacotherapy, ensuring alignment with both international standards and national healthcare policies. Future research should focus on integrating pharmacoeconomic assessments into clinical decision-making and updating national treatment protocols accordingly.

30 December 2025 in Problems of Cryobiology and Cryomedicine
Verified
Journal Article
Closed access
VSValentyn Shapovalov
Valentyn Shapovalov
ONOleksandr Nevzghoda
Oleksandr Nevzghoda
VSViktoriia Shapovalova
Viktoriia Shapovalova
АОАліна Осинцева
Аліна Осинцева
The paper considers the legal and bioethical foundations of the activity of cryobanks of human cells and tissues in Ukraine. The importance of adapting national legislation to international standards in the field of biobanking, transplantology and assisted reproductive technologies is shown. The study provides an analysis of the basics of legal regulation of cryobanks, identifies directions for improving the legislation of Ukraine in accordance with European standards. For the analysis, the authors were guided by the laws of Ukraine, directives of the European Union, recommendations of the World Health Organization, documents of the Council of Europe, and used scientific publications in the field of medical law, bioethics, cryobiology, and reproductive medicine. Regulatory, documentary, comparative methods of analysis were applied. It has been established that the current regulatory framework for governing the activities of cryobanks is fragmented, does not determine the legal status of biological material, the procedure for its inheritance and use after the donor’s death. The proposed ways to improve the legal field are as follows: adoption of a special law on biobanks, creation of a unified state register of biological samples, adaptation of protocols and procedures to the norms of the European Union. The implementation of the proposed measures will contribute to the transparency, ethics, and efficiency of cryobanks, the protection of the rights of donors and patients, and the development of biomedical research in Ukraine.

1 April 2025 in SSP Modern Pharmacy and Medicine
Verified
Journal Article
Open access
PDF file
ONOleksandr Nevzghoda
Oleksandr Nevzghoda
ANAnatolii Nevzghoda
Anatolii Nevzghoda
For the first time in Ukraine, our team successfully applied extracorporeal blood hyperthermia (EBH) within a closed-loop circuit to manage inflammatory conditions of the lungs and pleura. Controlled warming of autologous blood to 38°C and its subsequent reinfusion produced rapid, clinically significant reductions in exudative pleurisy, pleural empyema, and paracancerous inflammatory lesions. Earlier, EBH had been incorporated into U.S. military field protocols between 2003 and 2007, and it is now formally included in therapeutic guidelines across the United States, Canada, New Zealand, multiple European nations, and several African healthcare systems. Our findings corroborate international data showing that mild systemic hyperthermia enhances phagocytic activity, improves microcirculation within the pleural cavity, and accelerates resorption of inflammatory exudate while maintaining a favorable safety profile. No severe adverse events or hemodynamic instabilities were observed during or after the procedures in our cohort. Beyond its direct anti-inflammatory impact, EBH may potentiate antibiotic penetration into pleural tissues, offering a valuable adjunct in the era of rising antimicrobial resistance. Future multicenter trials with larger patient populations and comparative cost-effectiveness analyses are warranted to refine treatment parameters and confirm long-term benefits of this promising modality.

1 January 2025 in SSP Modern Pharmacy and Medicine
Verified
Journal Article
Open access
PDF file
ONOleksandr Nevzghoda
Oleksandr Nevzghoda
ANAnatolii Nevzghoda
Anatolii Nevzghoda
The healthcare sector is faced with the need to find new innovative and multidisciplinary approaches for the prevention and treatment of Covid, post-Covid, long-Covid, chronic, comorbid disorders. The results of 30 years of experience in the use of halotherapy in the treatment of pulmonary pathology indicate that the authors of the article have established the optimal level of use of halotherapy in pathological pulmonary processes. At the same time, clinical experience provides evidence for the optimal method of using the halotherapy method in pulmonary nosologies. The method of using salt therapy in exudative pleurisy, in fibrinous pleurisy, in fibrotic processes in the lungs has been theoretically substantiated, developed, and implemented in clinical practice. It has been proven that halotherapy is an effective treatment method for bronchial asthma, chronic obstructive pulmonary diseases, acute respiratory viral infections, fibrinous and exudative pleurisy. The therapeutic effect of this method is observed only when using halogenerators with the ability to grind salt in the range of 1-5 microns. Halotherapy sessions in patients with bronchial asthma with mild and moderate severity lead to the development of nonspecific hyposensitization, which in turn provides long-term remission of attacks and reduces the need for glucocorticosteroid drugs. Halotherapy has a confirmed immunomodulatory effect and activates local and T-cell immunity. It requires further study of the experience of halotherapy, conducting marketing, pharmacoeconomic and comparative analysis.